Reporte zur Charge PF1315FJ4991

Symptomtext

Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient. A 67-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 07Jul2022 as dose 4 (booster), single (Lot number: PF1315FJ4991), in left arm for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown) and as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Severe coronary artery disease" (unspecified if ongoing), notes: Severe coronary artery disease; "Smoking" (unspecified if ongoing), notes: Smoking; "lung nodules" (unspecified if ongoing); "Known allergies: Sulpha" (unspecified if ongoing), notes: Known allergies: Sulpha; "Known allergies: Penicillin" (unspecified if ongoing); "Known allergies: Adhesives" (unspecified if ongoing), notes: Known allergies: Adhesives; "Known allergies: Dairy" (unspecified if ongoing), notes: Known allergies: Dairy; "Known allergies: Gluten" (unspecified if ongoing), notes: Known allergies: Gluten. The patient took concomitant medications. Other medication in 2weeks reported as Yes. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Oct2022, outcome "unknown" and all described as "Treatment of COVID-19". Seriousness reported as No. Therapeutic measures were taken as a result of drug ineffective, covid-19 with Anti-viral treatment with Paxlovid taken from 08Oct2022 and stopped on 15Oct2022.